Bogdan A. Stana

Latest posts by Bogdan A. Stana (see all)

OBEZITATEA SI DISLIPIDEMIILE LA COPILUL CU HEPATITA CRONICA - 29/08/2016
OBESITY AND DYSLIPIDEMIA IN CHILDREN WITH CHRONIC HEPATITIS - 29/08/2016
Ursodeoxycholic acid benefit in pediatric non-alcoholic fatty liver disease - 23/07/2015

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

OBEZITATEA SI DISLIPIDEMIILE LA COPILUL CU HEPATITA CRONICA

Revista Romana de PEDIATRIE | Volumul LXV, Nr. 2, An 2016

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

Alice N. Azoicai, Alina M. Murgu, Bogdan A. Stana, Evelina Moraru, Ileana K. Ioniuc, Irina Criscov, Monica M. Alexoae and Paula Popovici

REZUMAT

Asocierea hepatitelor cronice cu diverse tipuri de dislipidemii este o realitate nu numai pentru pacientul obez, la care ne aşteptăm să găsim hipercolesterolemii sau/şi hipertrigliceridemii, dar şi pentru copilul normoponderal. Cauzele acestei asocieri sunt multiple, însă trebuie să avem în vedere, în primul rând, predispoziţia familială şi transmiterea genetică a unor forme de dislipidemii. În acelaşi timp, unele dislipidemii sunt secundare hepatopatiilor cronice, astfel că se formează un cerc vicios în care tratamentul de primă intenţie a dezechilibrelor metabolice este de mare importanţă în succesul terapiei antivirale.

Cuvinte cheie: hepatită, dislipidemie, obezitate, copil

Full text | PDF

Alice N. Azoicai

OBESITY AND DYSLIPIDEMIA IN CHILDREN WITH CHRONIC HEPATITIS

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

Alice N. Azoicai, Alina M. Murgu, Bogdan A. Stana, Evelina Moraru, Ileana K. Ioniuc, Irina Criscov, Monica M. Alexoae and Paula Popovici

ABSTRACT

Chronic hepatitis association with various types of dyslipidemia is a reality not only for the obese pediatric patient, in which we expect to find hypercholesterolemia and / or hypertriglyceridemias, but also for normal weight children with hepatitis. The causes of this association are multiple, but we need to consider first the innate predisposition and transmission of genetic forms of dyslipidemia. Meanwhile, some secondary dyslipidemia are chronic liver disease related. Those considerations are forming a vicious circle in which primary treatment of metabolic imbalances has a great importance for the success of antiviral therapy.

Keywords: hepatitis, dyslipidemia, obesity, children

Full text | PDF

Alice N. Azoicai

Ursodeoxycholic acid benefit in pediatric non-alcoholic fatty liver disease

Revista Romana de PEDIATRIE | Volumul LXII, Nr. 1, An 2013

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

Otilia E. Frăsinariu, Laura Bozomitu, Alice Azoicăi, Bogdan A. Stana, Paula Popovici and Evelina Moraru

REZUMAT

Introduction. Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease in children, encompasses a range of disease from simple steatosis to steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been used in adult pacients with NASH, demonstrating its efficacy in high doses.

Purpose. The aim of our study was to assess the effect of high-dose ursodeoxycholic acid therapy on liver functions in children with NASH.

Methods. We prospectively studied 18 children with NASH aged 2.5 to 17 years. NASH was operationally defined as diffusely hyperechogenic liver at ultrasonography with persistently elevated (> 35 UI/l) alanine aminotransferase (ALT) or aspartate aminotransferaze (AST) after exclusion of viral, alcohol-induced, druginduced, cholestatic and genetic causes of liver disease. Patients were treated with ursodeoxycolic acid (20 mg/ kg per day) for six month.

Results. Treatment with UDCA significantly decreased hepatic transaminases. ALT levels ranged from 68.5 (50-166) at baseline vs. 47 (29-104) after six month, p <0.001, AST from 43 (29-101) 34 (17-75), p < 0.001, and GGT between 41.5 (11-150) vs. 22 (8-55). At the end of treatment, ALT levels normalized in 4 patients. Moreover, cholesterol levels were significantly reduced after treatment.

Conclusions. Treatment with high-dose ursodeoxycholic acid improves liver function parameters in children with NASH.

Cuvinte cheie: steatoză hepatică, acid ursodeoxicolic, transaminaze hepatice

Full text | PDF

Otilia E. Frăsinariu

BENEFICIUL ACIDULUI URSODEOXICOLIC IN STEATOZA HEPATICA NON-ALCOOLICA LA COPIL

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

Otilia E. Frăsinariu, Laura Bozomitu, Alice Azoicăi, Bogdan A. Stana, Paula Popovici and Evelina Moraru

REZUMAT

Introducere. Boala ficatului gras non-alcoolic (NAFLD), cea mai frecventă cauză a bolii hepatice cronice la copii, cuprinde un spectru de afecţiuni variind de la steatoză simplă până la steatohepatită (NASH). Acidul ursodeoxicolic (UDCA) a fost utilizat la pacienţi adulţi cu NASH, demonstrându-şi eficacitatea în doze crescute.

Scop. De a evalua efectul tratamentului cu doze crescute de UDCA asupra parametrilor funcţiei hepatice la copii cu NASH.

Metode. Lotul de studiu a fost constituit din 18 copii cu NASH cu vârste cuprinse între 2,5 şi 17 ani. NASH a fost operaţional definit ca ficatul difuz hiperechogenic la ecografie cu valori persistent crescute (> 35 UI/l) ale alanin aminotransferazei (ALAT) sau aspartat aminotransferazei (AST), după excluderea cauzelor virale, drog sau alcool induse, colestatice sau genetice ale bolii hepatice. Pacienţii au fost trataţi cu acid ursodeoxicolic (20 mg/kg/zi), timp de şase luni.

Rezultate. Tratamentul cu UDCA a determinat scăderea semnificativă a valorilor transaminazelor hepatice. Nivelurile ALT au variat între 68,5 (50-166) iniţial vs 47 (29-104) după şase luni, p < 0,001, AST între 43 (29-101) vs 34 (17-75), p < 0,001, şi GGT între 41,5 (11-150) vs. 22 (8-55). La sfârşitul tratamentului, niveluri ALT s-au normalizat la 4 dintre pacienţi. De asemenea, concentraţiile de colesterol au fost semnificativ reduse după tratament.

Concluzii. Tratamentul cu doze crescute de acid ursodeoxicolic imbunătăţeşte parametrii funcţiei hepatice la copii cu NASH.

Cuvinte cheie: steatoză hepatică, acid ursodeoxicolic, transaminaze hepatice

Full text | PDF

Otilia E. Frăsinariu

Arhiva autor

Bogdan A. Stana

Latest posts by Bogdan A. Stana (see all)

Articole semnate de acelasi autor in Revista Romana de Pediatrie:

OBEZITATEA SI DISLIPIDEMIILE LA COPILUL CU HEPATITA CRONICA

SELECT ISSUE

Indexed

HIGHLIGHTS